The effect of respiratory disease and a preventative antibiotic treatment on growth, survival, age at first calving, and milk production of dairy heifers.
Bovine respiratory disease complex (BRD) is a common disease in weaned dairy calves that incurs economic and welfare costs. This study was an extension of a randomized clinical trial in which a single injection of tulathromycin (TUL) or oxytetracycline (TET) was administered at first movement to group housing for the prevention of BRD in the 60 d following antimicrobial treatment (BRD60). Calves treated with TUL were 0.5 times [95% confidence interval (CI): 0.4 to 0.7] as likely to be treated for BRD60 as calves treated with TET. The objectives of the current study were to evaluate the long-term effects of BRD and antibiotic treatment on growth of heifers until breeding age, age at first calving, incidence of dystocia, milk production, and mortality before first calving and mortality before 120 d in milk. At entry to the breeding barn (382 d of age), calves that experienced BRD60 weighed 16.0±2.3 kg less than calves that did not. Survival to first calving was recorded for 98% (1,343/1,392) of the heifers on this trial. For TET and TUL heifers with BRD60, 63% (94/150) and 73% (64/88) survived to first lactation, respectively. For TET and TUL calves without BRD60, 84% (436/517) and 84% (494/588) survived to first lactation, respectively. The median age at first calving for heifers with and without BRD60 was 714 (95% CI: 705-723) and 702 (95% CI: 699-705) days, respectively. Heifers with BRD60 were 1.5 (95% CI: 1.1-2.2) times more likely to have a calving ease score ≥2 at their first calving compared with heifers without BRD60. The administration of TUL at movement to group housing may have a role in the prevention of BRD and in mitigating some of the long-term effects of this disease.
Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1. Electronic address: astanton@uoguelph.ca.
A L
AL
Stanton
Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1.
D F
DF
Kelton
Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1.
S J
SJ
LeBlanc
CY Heifer Farm, Batavia, NY 14020.
J
J
Wormuth
Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1.
K E
KE
Leslie
D000367:Age Factors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D048090:Bovine Respiratory Disease Complex / Q000401:mortality / Q000503:physiopathology* / Q000517:prevention & control; D002417:Cattle / Q000254:growth & development; D004187:Disaccharides / Q000627:therapeutic use*; D005260:Female; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D007774:Lactation / Q000187:drug effects / Q000502:physiology*; D010118:Oxytetracycline / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000662:veterinary; D018942:Macrolides
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D010118:Oxytetracycline; C485204:tulathromycin; D018942:Macrolides